130.32
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ILMN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$126.96
Offen:
$126.79
24-Stunden-Volumen:
1.14M
Relative Volume:
0.59
Marktkapitalisierung:
$19.80B
Einnahmen:
$4.34B
Nettoeinkommen (Verlust:
$850.00M
KGV:
23.85
EPS:
5.4635
Netto-Cashflow:
$921.00M
1W Leistung:
+3.07%
1M Leistung:
+9.57%
6M Leistung:
+43.21%
1J Leistung:
+73.62%
Illumina Inc Stock (ILMN) Company Profile
Firmenname
Illumina Inc
Sektor
Branche
Telefon
(858) 202-4500
Adresse
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
ILMN
Illumina Inc
|
130.32 | 18.37B | 4.34B | 850.00M | 921.00M | 5.4635 |
|
TMO
Thermo Fisher Scientific Inc
|
527.22 | 184.37B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
198.61 | 134.19B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
584.05 | 44.72B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
120.39 | 32.52B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
330.98 | 31.41B | 3.17B | 642.63M | 516.49M | 10.77 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-07-11 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | Bestätigt | Citigroup | Neutral |
| 2025-02-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-02-10 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-11-12 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-08-28 | Hochstufung | Argus | Hold → Buy |
| 2024-08-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-11-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Eingeleitet | Bernstein | Underperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Neutral |
| 2023-01-25 | Herabstufung | Argus | Buy → Hold |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Perform |
| 2022-12-12 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-04 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-07-13 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Hochstufung | Stifel | Hold → Buy |
| 2022-01-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Eingeleitet | Barclays | Underweight |
| 2020-12-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-10-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Herabstufung | Stifel | Buy → Hold |
| 2020-09-22 | Herabstufung | UBS | Buy → Neutral |
| 2020-09-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Illumina Inc Aktie (ILMN) Neueste Nachrichten
How Investors Are Reacting To Illumina (ILMN) Board Turnover And Expanded Labcorp Precision Oncology Partnership - simplywall.st
Illumina partners with D3b on pediatric genomic data initiative - Investing.com
Illumina Partners with D3b to Advance Pediatric Cancer Research - Intellectia AI
100,000 child genomes power rare disease and cancer research - Stock Titan
Third View Private Wealth LLC Buys Shares of Illumina, Inc. - National Today
Administrator Loeffler Applauds SBIR-STTR Reauthorization - GlobeNewswire Inc.
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Hardman Johnston Trims Illumina Stake - National Today
Bioinformatics Market 2026- 2033 Overview: Share, Size, Value, - openPR.com
Illumina (ILMN), Labcorp (LH) Expand Precision Oncology NGS Collaboration - Insider Monkey
Epigenetics Market to Grow from US$ 2.06 Billion in 2024 to US$ - openPR.com
Illumina Inc. stock (US4523271090): Is its genomics leadership strong enough for long-term U.S. inve - AD HOC NEWS
Is It Time To Reassess Illumina (ILMN) After Its 61.7% One Year Share Price Rebound - Yahoo Finance
Is Illumina Stock Undervalued at $121? - TIKR.com
Illumina Inc stock (US4523271090): Is its genomics dominance strong enough to unlock new upside? - AD HOC NEWS
Illumina Inc. stock outperforms competitors despite losses on the day - MarketWatch
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Global Next-Generation Sequencing (NGS) Market to Double in Size by 2030 - GlobeNewswire Inc.
Illumina Stock: Competitive Threats Priced In (NASDAQ:ILMN) - Seeking Alpha
Illumina Inc (ILMN) Stock Down 3.4% -- Now Undervalued? GF Score: 83/100 - GuruFocus
Informatics advances reveal the TruPath™ Genome towards comprehensive genomic insights - Illumina
Illumina Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026 - marketscreener.com
Illumina Inc. stock rises Wednesday, still underperforms market - MarketWatch
(ILMN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Illumina, Inc. (ILMN) Stock Forecasts - Yahoo Finance
New Zealand gains genomic testing independence - Illumina
Illumina, Inc. $ILMN Shares Sold by Aberdeen Group plc - MarketBeat
The Evolving Landscape of Proteomics: HUPO World Congress Interview with Professor Stuart Cordwell - Illumina
Illumina rejigs board of directors - Medical Buyer
Cathie Wood's Called It Years Ago – Illumina Is the Must-Own Personalized Biotech Stock - Money Morning
Illumina, Inc. (ILMN) stock price, news, quote and history - Yahoo Finance Singapore
Illumina Inc (ILU.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Illumina, Inc. (ILMN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Illumina Stock Hits Day Low of $116.75 Amid Price Pressure - Markets Mojo
Cancer Biopsy Market Set to Boom Rapidly, Witnessing Strong - openPR.com
Liquid Biopsy Products Market Is Going to Boom | Illumina • Biocept • Natera • Roche - openPR.com
Illumina, Inc. (ILMN) latest stock news and headlines - Yahoo Finance Singapore
Illumina adds King to board as three directors retire By Investing.com - Investing.com Australia
Illumina Announces Changes to Board of Directors - The Malaysian Reserve
Illumina (ILMN) director Scott Ullem takes 2026 retainer as 190 ILMN shares - Stock Titan
Illumina (NASDAQ: ILMN) director paid in stock, linked to Corvex funds - Stock Titan
Illumina's 'Obvious Mistake' Not Enough To Chuck UPC Claim - Law360
UPC refuses early knockout in Illumina–Element dispute - Life Sciences Intellectual Property Review
Illumina, Inc. Announces Board Retirements, Effective May 21, 2026 - marketscreener.com
Illumina adds King to board as three directors retire - Investing.com
Illumina Announces Board Retirements and New Director Nominee - TipRanks
Illumina (NASDAQ: ILMN) nominates David P. King as three directors retire - Stock Titan
AAV Genome Sequencing Service Market Is Booming Rapidly with - openPR.com
Exosome Research Market is Thriving Worldwide | Thermo Fisher Scientific, Illumina Inc, Miltenyi Biotec, QIAGEN - openPR.com
An Illumina milestone powered by our people: 100,000 volunteer hours - Illumina
Finanzdaten der Illumina Inc-Aktie (ILMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):